IMC:ASX
Immuron Ltd
A$0.034
0.00%
(0.00) 1D
Oct 16, 10:43:31 AM GMT+11 · AUD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IMC...
Mkt. cap
10.98M
Avg. vol.
711.54K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
8
Mkt. cap
10.98M
Avg. vol.
711.54K
Volume
0.00
52-wk high
A$0.10
52-wk low
A$0.03
EPS
-A$0.01
Shares outstanding
322.85M
No. of employees
8
News stories
From web sources and news partners
TradingView
·
42 minutes ago
S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
RealMoney Pro
·
43 minutes ago
Charting the Markets: The S&P Is Still Bullish. But for How Long?
GuruFocus
·
46 minutes ago
Bank of America Securities Upgrades Dow Inc. (DOW) to Neutral on Rising Chemical Prices
Insider Monkey
·
1 hour ago
Apple Has Outperformed the S&P 500, but is AAPL’s 35x Valuation Getting Ahead of its Growth?
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Victoria, Australia
SectorBiotechnology
Websiteimmuron.com.au